Meta-analysis

Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials

Eur J Prev CardiolPublished

  • Systematic review and meta-analysis of randomised trials
  • random-effects model
  • PRISMA

Authors' conclusion

This meta-analysis suggest that semaglutide is associated with a significant reduction in major limb events across diverse populations and treatment settings, supporting a potential protective effect on limb-related vascular safety.

Study context

Population
Individuals with T2DM and/or overweight or obesity
Participants
51,557 individuals · 19 RCTs
Comparison
Semaglutide vs control
Outcome
Major limb events (revascularizations, amputations, peripheral artery disease (PAD) progression); prespecified safety outcomes in the original trials

Pooled result

Limb events

Odds ratio

0.70

95% CI 0.60–0.82

P < 0.0001

Semaglutide vs Control
OR 0.70 (95% CI 0.60–0.82); P < 0.0001

As reported in the abstract

Further pooled results

OutcomeOR (95% CI)P value
Limb events, by subgroup — Semaglutide vs Control · diabetes0.70 (0.57–0.87)P = 0.001
Limb events, by subgroup — Semaglutide vs Control · obesity0.71 (0.56–0.89)P = 0.003
OutcomeEstimateP value
Limb events, by subgroup — Semaglutide vs Control · oral formulation0.71 (95% CI 0.53–0.94)P = 0.02
Limb events, by subgroup — Semaglutide vs Control · subcutaneous 1.0 mg0.68 (95% CI 0.49–0.95)P = 0.02
Limb events, by subgroup — Semaglutide vs Control · subcutaneous 2.4 mg0.71 (95% CI 0.57–0.89)P = 0.003

Limb events, by subgroup

Benefit consistent regardless of background SGLT2 inhibitor use

Meta-regression

No significant effect modification by age, BMI, HbA1c, follow-up duration or SGLT2i use

Original publication

Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. Published 9 February 2026. doi:10.1093/eurjpc/zwag077

Summarised from the published abstract; every number is checked against it